Interim Report April

EQL reported a weak start to the new fiscal year: Q1 sales were SEK 106.9m vs SEK 107.2m prior period (roughly flat), while OPEX rose to SEK 31.5m from SEK 25.7m. Reported gross margin fell to 17% (from 43%) and EBITDA margin to -6% (from 24%), driven by SEK 20m inventory write-downs; adjusted margins were 35% gross and 12% EBITDA. Management attributes delays to supply disruptions and more technically complex product launches, with the article indicating continued pressure near-term.

Analysis

The market should separate the inventory write-down from the real signal: launch complexity plus supply disruption usually mean the earnings hit is less about one bad quarter and more about a higher-error operating model. If the company is forced to carry more buffer stock while product launches remain delayed, gross margin can look volatile for several quarters because fixed-cost absorption and obsolescence risk both rise at the same time.

The second-order effect is competitive share loss, not just lower near-term sales. In technically complex product categories, customers that experience fulfillment delays tend to re-source to vendors with cleaner manufacturing validation and faster release cadence, which can become sticky over 6-18 months. That makes the key question whether this is a temporary logistics issue or evidence that the launch pipeline is outpacing the company’s execution capacity.

Contrarian takeaway: the headline margin collapse is probably not the right way to handicap the name; normalized gross margin excluding write-downs suggests the underlying business is still viable. The real risk is that the company keeps “earning back” margin through adjustments while the product cadence slips again, which would force multiple compression on any recovery rally. Falsification would be a clean next-quarter guide with no further inventory charges and evidence that the newly launched products are scaling without additional opex drag.

Key Decisions for Investors

• No single-name trade is warranted from this release alone; treat it as a watch item and require one more quarter of data on gross margin ex-write-downs, inventory days, and launch timing before taking risk.
• For a relative-value expression on the operating-quality theme, consider long MDT / short XHE over 1-3 months if the broader medtech tape weakens on similar execution issues; this favors companies with stronger supply-chain control and lower launch risk.
• If you want to fade the overreaction, wait for any post-print selloff to stabilize and only add on evidence of margin normalization above the mid-30s ex-write-downs; if that level fails again, the downside likely extends another 10-15% as credibility risk rises.
• Set an alert for the next quarterly update: if inventory write-downs repeat or management cuts launch guidance, the thesis shifts from transitory disruption to structural execution impairment, and that would justify a short or underweight stance.